When characterizing molecular targets for potential prognostic and therapeutic use, differences in the sex distribution have led to the investigation of the role of estrogen receptors (ER) in the development and progression of pancreatic cancer and other malignancies [6–11]. This evidence concerns the gene ESR1 and familial pancreatic carcinoma.